Drugs / HydroEye®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04163328 | Sep 2022 → Aug 2024 | dry eye syndrome | University of Alabama at Birmingham | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HydroEye | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04163328 ↗ |
| Route | Oral | “two capsules taken orally, twice a day” NCT04163328 ↗ |